PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29908090-3	2018	EXPERIMENTAL APPROACH: We identified and analysed mutations in the RET kinase domain that conferred resistance to the TKIs cabozantinib, lenvatinib, vandetanib and nintedanib using RET kinase-dependent BaF3/KIF5B-RET (BaF3/KR) cells.	lenvatinib	137-147	kinesin family member 5B	Homo sapiens	207-212	
23856031-4	2013	In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET.	lenvatinib	20-30	kinesin family member 5B	Homo sapiens	65-70	
25625428-2	2015	Several related clinical trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene.	lenvatinib	140-150	kinesin family member 5B	Homo sapiens	76-81